The Chinese biopharmaceutical sector has experienced a remarkable turnaround, entering 2026 with significant momentum. In 2025, the value of outbound licensing and drug development agreements reached nearly $136 billion, marking a 161% increase compared to the previous year. This surge reflects a series of lucrative drug approvals and supportive policy changes from Chinese authorities aimed at accelerating the introduction of innovative drugs to the market.
Record Growth in Drug Approvals and Investments
The biopharma landscape in Hong Kong witnessed a renaissance last year, highlighted by a 76% increase in the Hang Seng Healthcare Index (HSHCI). This growth significantly outperformed the broader Hang Seng benchmark and eclipsed the nearly 26% gain of pharmaceutical stocks in mainland China. The resurgence can be attributed to a record influx of Chinese capital into Hong Kong equities, with southbound capital flows from Chinese investors reaching a net HK$1.4 trillion ($180 billion) in 2025. Investments in the healthcare sector alone surged by 126% to HK$540 billion, enhancing liquidity and encouraging further investment.
The sector also benefited from a surge in licensing and partnership deals, which contributed to a boom in earnings for drugmakers. Business development transactions worth over $130 billion provided a substantial boost, leading to increased equity trading volumes and rising share prices. However, not all companies shared equally in this success; those with strong drug prospects and established commercial pipelines reaped most of the benefits, while investors remained cautious of firms with limited product offerings or those still in early development stages.
Companies providing outsourced drug services experienced strong performance, with Weigao Group (1066.HK) seeing a 38% rise and MicroPort Scientific (0853.HK) achieving an impressive 76% increase in shares. Conversely, some dental and medical aesthetics firms struggled, with stocks in Arrail Group (6639.HK) and Giant Biogene (2367.HK) falling by nearly 40% as consumer spending on non-essential medical services declined.
Regulatory Support and Future Outlook
The supportive policy environment for Hong Kong listings has further bolstered market activity. In 2025, over 90 biopharmaceutical companies applied to join the Hong Kong exchange, with more than 20 successfully listing, doubling the number from the previous year. Notable successes included Hengrui Pharma (1276.HK; 600276.SH), which raised HK$11.3 billion, ranking among the top five Hong Kong IPOs of 2025. Following the IPO, Hengrui’s shares have since increased by over 30%.
International partnerships have also played a pivotal role in the sector’s growth. By the end of 2025, the total value of outbound licensing and business development deals for innovative drugs rose to $135.66 billion, an annual increase of 161%. Upfront payments totaled $7 billion, with a record 157 transactions completed. A landmark agreement between Hengrui and pharmaceutical giant GSK involved 12 innovative drug programs, providing the Chinese company with $500 million upfront and potential milestone payments and options worth up to $12 billion.
Looking ahead, the easing of credit conditions in the United States and initiatives to include more innovative drugs in China’s medical system are expected to support profitability for leading firms such as BeiGene (688235.SH; 6160.HK). The introduction of a commercial insurance catalogue for innovative drugs by the National Medical Products Administration in December 2025 marks a significant policy shift, combining basic medical insurance with commercial coverage. This new model is expected to enhance clinical treatment standards and improve returns on research and development investments, particularly benefiting companies with extensive drug pipelines such as BeiGene, Innovent Biologics, and Akeso.
Despite these positive developments, challenges remain. The expected expiry of post-listing lockups this year may trigger a wave of selling, potentially dampening market enthusiasm. Additionally, increased scrutiny from stock market regulators could lead to stricter IPO vetting processes. Recently, Hong Kong securities regulators issued warnings to IPO sponsors regarding declining application quality and compliance issues, indicating that tighter oversight may be on the horizon.
While some companies have successfully transitioned out of pre-revenue status, many still grapple with converting research investments into marketable products. Only medical device maker Zylox-Tonbridge and drug developer Everest Medicines have managed to move beyond this stage, highlighting the persistent challenges within the sector.
As the Chinese biopharma sector continues to navigate these complexities, the momentum generated in 2025 sets the stage for a potentially transformative year ahead.
